Neurogen Biomarking

San Diego, United States· Est. 2018

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Neurogen Biomarking, founded in 2018 and based in San Diego, is developing a direct-to-consumer diagnostic platform for the early detection of Alzheimer's disease. Its core offering is an integrated 'Memory Health ecosystem' that includes an at-home blood test kit, online cognitive screening, and personalized review and guidance from board-certified neurologists. The company is currently in a beta launch phase, positioning itself to capitalize on the growing demand for accessible, pre-symptomatic Alzheimer's testing enabled by recent advances in blood-based biomarkers. Neurogen's model bridges consumer diagnostics with clinical expertise, aiming to facilitate earlier intervention and personalized care planning.

Alzheimer's DiseaseNeurology

Technology Platform

Integrated 'Memory Health ecosystem' combining at-home blood-based biomarker testing for Alzheimer's disease, digital cognitive assessments, and telehealth consultations with board-certified neurologists for result interpretation and care planning.

Opportunities

The recent approval of disease-modifying Alzheimer's therapies that require early diagnosis creates a massive, timely need for accessible testing.

The shift to blood-based biomarkers enables a scalable direct-to-consumer model, tapping into the growing market for proactive health and wellness.

Neurogen's integrated ecosystem differentiates it from pure-play test providers, potentially creating higher value and customer retention.

Risk Factors

Regulatory uncertainty surrounds direct-to-consumer lab-developed tests, and lack of insurance reimbursement limits the addressable market.

Intense competition is emerging from large diagnostic labs and biotech firms.

Convincing asymptomatic individuals to seek testing and pay out-of-pocket presents a significant adoption hurdle.

Competitive Landscape

Neurogen competes in the rapidly growing blood-based Alzheimer's diagnostic market. Major competitors include large commercial labs (Quest Diagnostics, Labcorp), specialized diagnostic companies (C2N Diagnostics), and potentially digital cognitive assessment tools alone. Neurogen's key differentiator is its vertically integrated service combining the test, digital tools, and neurologist guidance, aiming for a superior end-to-end customer experience compared to disaggregated offerings.